Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium
about
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelEfficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditisAntibiotic resistance: a current perspective.Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.Vancomycin-resistant enterococci.Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic modelActivity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionExperimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitisOritavancin diphosphateIntracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinationsThe management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.
P2860
Q33593883-662A020F-B857-4626-B2D4-3CA8512DD5BAQ33693084-C5F6B911-70D5-40EF-9757-B43A6233A63EQ33693954-953B210F-99EB-4F84-83B3-6593757FEF86Q33697206-00692B9F-3C57-4472-B83B-1A4E289DCB59Q33697465-0D9BBBDF-D617-4B72-98A2-C2A6784932AAQ33975592-1CCC35A9-0318-4300-9A50-EC635E386078Q33975885-C3D392E7-6350-42C1-97BF-A81277C6C6A7Q33976444-215C4B9B-7351-491D-A5C3-7FFBE1582E1DQ33981579-5D2213DD-888B-4289-96E2-F57AAD0B2570Q34937444-73451028-3A5A-44C8-90B9-1C0D002C916DQ35013994-3E1FFBD8-378B-4603-BC5C-F7EC989AE4DBQ35057973-7C75EF8A-85DF-43EF-83FD-2B0F9615A839Q37144883-D10BD77A-20A6-421A-A45A-28F12F64DF79Q40667218-9526B80F-4D7E-4219-8FF4-DC3899F16F12
P2860
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Pharmacodynamic evaluation of ...... ureus and Enterococcus faecium
@ast
Pharmacodynamic evaluation of ...... ureus and Enterococcus faecium
@en
type
label
Pharmacodynamic evaluation of ...... ureus and Enterococcus faecium
@ast
Pharmacodynamic evaluation of ...... ureus and Enterococcus faecium
@en
prefLabel
Pharmacodynamic evaluation of ...... ureus and Enterococcus faecium
@ast
Pharmacodynamic evaluation of ...... ureus and Enterococcus faecium
@en
P2093
P2860
P356
P1476
Pharmacodynamic evaluation of ...... ureus and Enterococcus faecium
@en
P2093
H H Houlihan
R C Mercier
P2860
P304
P356
10.1128/AAC.41.6.1307
P407
P577
1997-06-01T00:00:00Z